Trametinib
Brand: Mekinist (global)
Anticancer
MEK inhibitor
Pharmacokinetics
| Half-life | 4 days |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Given once daily. Half-life long (~4 days). Combined with Dabrafenib for best outcomes. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Cardiomyopathy, retinopathy, diarrhea, hypertension, ILD
Contraindications:
Severe cardiac failure
Precautions:
Monitor cardiac EF and ophthalmology if visual symptoms.